Improving the cytometric detection of doxorubicin resistance in osteosarcoma cells by determining cellular doxorubicin/DNA ratio

Anticancer Research

Volumn 19, Issue 6 B, 1999, Pages 5235-5238

  Takeshita, Hideyuki ^a,b,c   Kusuzaki, Katsuyuki ^a   Murata, Hiroaki ^a   Nakamura, Shin Ichiro ^a   Ashihara, Tsukasa ^a   Hirasawa, Yasusuke ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b OTSU MUNICIPAL HOSPITAL   (Japan)

^c Otsu Municipal Hospital   (Japan)

Author keywords

DNA content; Doxorubicin; Drug resistance; Osteosarcoma

Indexed keywords

CELL DNA; DOXORUBICIN; GLYCOPROTEIN P;

ANIMAL CELL; ARTICLE; CELL LEVEL; CYTOMETRY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PLOIDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA, NEOPLASM; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; MICE; OSTEOSARCOMA; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0033377111     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ling V: P-glycoprotein: its role in drug resistance. Am J Med 99 (Suppl): 31S-34S, 1995.
2. Germann UA: P-glycoprotein-A mediator of multidrug resistance in tumor cells. Eur J Cancer 32A: 927-944, 1996.
3. Nooter K, van den Engh G, Sonneveld P: Quantitative flow cytometric determination of anthracyclin content of rat bone marrow cells. Cancer Res 43: 5126-5130, 1983.
4. Herweijer H, van den Engh G, Nooter K: A rapid and sensitive flow cytometric method for the detection of multidrug-resistant cells. Cytometry 10: 463-468, 1989.
5. Kusuzaki K, Takeshita H, Murata H, Hirata M, Hashiguchi S, Ashihara T, and Hirasawa Y: Relation between cellular doxorubicin binding ability to nuclear DNA and histologic response to preoperative chemotherapy in patients with osteosarcoma. Cancer (Phila) 82: 2343-2349, 1998
6. Frankfurt OS, Slocum HK, Rustum YM, Arbuck SG, Pavelic ZP, Petreli H, Huben RP: Flow cytometric analysis of DNA aneuploidy in primary and metastatic human solid tumors. Cytometry 5: 71-80, 1984.
7. Mankin HJ, Gebhardt MC, Springfield DS, Litwak MS, Kusuzaki K, Rosenberg A: Flow cytometric studies of human osteosarcoma. Clin Orthop 270: 169-180, 1991.
8. Yesair DW, Thayer PS, McNitt S, Teague K: Comparative uptake, metabolism, and retention of anthracyclins by tumors growing in vitro and in vivo. Eur J Cancer 16: 901-907, 1980.
9. Takeshita H, Gebhardt MC, Springfield DS, Kusuzaki K, and Mankin HJ: Experimental models for the study of drug resistance in osteosarcoma; P-glycoprotein-positive murine osteosarcoma cell lines. J Bone Joint Surg 78-A: 366-375, 1996.
10. Takeshita H, Kusuzaki K, Tsuji Y, Hirata M, Hashiguchi S, Nakamura S, Murata H, Ashihara T, and Hirasawa Y: Avoidance-of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209. Anticancer Res 18: 739-742, 1998
11. Lanks KW, Lehman JM: DNA synthesis by L929 cells following doxorubicin exposure. Cancer Res 50: 4776-4778, 1990.
12. Hansen MB, Niersen SE, Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989.
13. Tannock IF: Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 62; 1117-1133, 1978.
14. Ford JM, and Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990 .
15. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, and Pastan I: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124, 1989.
16. Ashihara T, Kamachi M, Urata Y, Kusuzaki K, Takeshita H, Kagawa K: Multiparametric analysis using autostage cytofluorometry. Acta Histochem Cytochem 19: 51-59, 1986.